dr. mirza on niraparib efficacy across ovarian cancer subgroups
Published 7 years ago • 219 plays • Length 1:30Download video MP4
Download video MP3
Similar videos
-
2:18
dr. mirza on efficacy of niraparib/bevacizumab combo in recurrent ovarian cancer
-
2:26
dr. mirza discusses niraparib dose modifications for ovarian cancer patients with low body weight
-
0:57
dr. mirza on impact of niraparib in ovarian cancer
-
1:41
dr. mirza on niraparib plus bevacizumab combo in ovarian cancer
-
1:35
dr. mirza on the phase iii nova trial in ovarian cancer
-
1:30
dr. mirza on the evolving treatment landscape in recurrent ovarian cancer
-
0:52
dr. mirza on safety profile of niraparib/bevacizumab in recurrent ovarian cancer
-
0:39
it’s ovarian cancer awareness month #ovariancancer #cancersucks #doctor #fyp #viral
-
9:25
results from the engot-ov16/nova trial: efficacy and safety of niraparib in ovarian cancer
-
3:08
ovarian cancer: optimizing treatment with niraparib
-
2:18
dr. mirza on final data of the nsgo-avanova2/engot-ov24 trial in ovarian cancer
-
3:23
niraparib significantly improves outcomes for ovarian cancer patients
-
2:11
dr. mirza on the rationale for the avanova trial in recurrent ovarian cancer
-
1:50
niraparib shows positive data, requires different dosing in ovarian cancer
-
5:13
treating ovarian cancer with niraparib: the nova trial
-
6:25
niraparib maintenance therapy for ovarian cancer
-
6:57
niraparib maintenance for recurrent ovarian cancer
-
2:17
combination therapy to treat ovarian cancer: promising results from the ananova trial
-
8:29
esmo 2019: dr. mirza on important trials with parp inhibitors in ovarian cancer